International conference «Actual approaches to the extremely preterm babies: International experience and Ukrainian realities» (Kyiv, Ukraine, March 5-6, 2013)
What is congenital nephrotic syndrome ,what is the definition of congenital nephrotic syndrome,what is the inheritance,what are the responsible genes ,what are the types of congenital nephrotic syndrome,what is the presentation ,diagnosis ,and treatment of congenital nephrotic syndrome, primary type and secondary type of congenital nephrotic syndrome
What is congenital nephrotic syndrome ,what is the definition of congenital nephrotic syndrome,what is the inheritance,what are the responsible genes ,what are the types of congenital nephrotic syndrome,what is the presentation ,diagnosis ,and treatment of congenital nephrotic syndrome, primary type and secondary type of congenital nephrotic syndrome
childhood hypertension is unique presentation by Dr. Hemraj Soni,
very compressive, complied,upgraded, presentation......will definative helpfull for paediatrician n resident doctor............
childhood hypertension is unique presentation by Dr. Hemraj Soni,
very compressive, complied,upgraded, presentation......will definative helpfull for paediatrician n resident doctor............
Національні настанови з регіоналізації перинатальної допомоги в УкраїніMCH-org-ua
Доповідь на міжнародній конференції «Сучасні підходи до виходжування глибоконедоношених дітей» (Київ, 5-6 березня 2013 р.)
http://motherandchild.org.ua/ukr/event/307
International conference «Actual approaches to the extremely preterm babies: International experience and Ukrainian realities» (Kyiv, Ukraine, March 5-6, 2013)
In collaboration with the New England Regional Genetics Network, the Weitzman Institute aims to improve access to genetics services for underserved populations by offering primary care provider educational support through a free five-part webinar series that aims to enhance provider knowledge, practice, and attitudes regarding genetic services.
III Curso Anemia Perioperatoria. "Nuevas Perpectivas del Patient Blood Management." Servicio de Anestesiología y Reanimación. Hospital Universitario Puerta de Hierro. Majadahonda (Madrid). 8 y 9 de Mayo. Acreditado CFC
Presentation by Andrei Romancenco at the International conference on Simulation-based training in medicine (Kyiv, Ukraine, March 19-20, 2015)
http://motherandchild.org.ua/eng/SimConf-2015
Система впровадження та реалізації симуляційного навчання в Одеському націона...MCH-org-ua
Володимир Артьоменко. Доповідь на Міжнародній конференції «Симуляційне навчання в медицині» (Київ, 19-20 березня 2015 р.)
http://motherandchild.org.ua/ukr/SimConf-2015
Стандартизація медичних практик в акушерстві та неонатологіїMCH-org-ua
Презентація на Національній підсумковій конференції за результатами впровадження україно-швейцарської Програми "Здоров’я матері та дитини" (Київ, 23 квітня 2015 р.)
http://motherandchild.org.ua/ukr/event/768
Telemedicine and electronic inventory: experience of the regionsMCH-org-ua
Presentation at the National Capitalization conference of the Swiss-Ukrainian Mother and Child Health Programme (Kyiv, Ukraine, April 23, 2015)
http://motherandchild.org.ua/eng/event/768
Presentation at the National Capitalization conference of the Swiss-Ukrainian Mother and Child Health Programme (Kyiv, Ukraine, April 23, 2015)
http://motherandchild.org.ua/eng/event/768
Efficient Management: Success Stories of Partner FacilitiesMCH-org-ua
Presentation at the National Capitalization conference of the Swiss-Ukrainian Mother and Child Health Programme (Kyiv, Ukraine, April 23, 2015)
http://motherandchild.org.ua/eng/event/768
Monitoring: approaches, achievements and perspectivesMCH-org-ua
Presentation at the National Capitalization conference of the Swiss-Ukrainian Mother and Child Health Programme (Kyiv, Ukraine, April 23, 2015)
http://motherandchild.org.ua/eng/event/768
Continuous post-graduate medical education at the local level: results and ma...MCH-org-ua
Presentation at the National Capitalization conference of the Swiss-Ukrainian Mother and Child Health Programme (Kyiv, Ukraine, April 23, 2015)
http://motherandchild.org.ua/eng/event/768
Заради кращих результатів в охороні здоров’я: Досвід та висновки Програми “Зд...MCH-org-ua
Презентація на Національній підсумковій конференції за результатами впровадження україно-швейцарської Програми "Здоров’я матері та дитини" (Київ, 23 квітня 2015 р.)
http://motherandchild.org.ua/ukr/event/768
Телемедицина та електронна інвентаризація: досвід областейMCH-org-ua
Презентація на Національній підсумковій конференції за результатами впровадження україно-швейцарської Програми "Здоров’я матері та дитини" (Київ, 23 квітня 2015 р.)
http://motherandchild.org.ua/ukr/event/768
eHealth (електронна охорона здоров’я) та медичні інформаційні системи MCH-org-ua
Презентація на Національній підсумковій конференції за результатами впровадження україно-швейцарської Програми "Здоров’я матері та дитини" (Київ, 23 квітня 2015 р.)
http://motherandchild.org.ua/ukr/event/768
Ефективне управління: історії успіху партнерських закладівMCH-org-ua
Презентація на Національній підсумковій конференції за результатами впровадження україно-швейцарської Програми "Здоров’я матері та дитини" (Київ, 23 квітня 2015 р.)
http://motherandchild.org.ua/ukr/event/768
Моніторинг: підходи, досягнення та перспективиMCH-org-ua
Презентація на Національній підсумковій конференції за результатами впровадження україно-швейцарської Програми "Здоров’я матері та дитини" (Київ, 23 квітня 2015 р.)
http://motherandchild.org.ua/ukr/event/768
Новаторські підходи до навчання медичних працівників та адміністраторів закла...MCH-org-ua
Презентація на Національній підсумковій конференції за результатами впровадження україно-швейцарської Програми "Здоров’я матері та дитини" (Київ, 23 квітня 2015 р.)
http://motherandchild.org.ua/ukr/event/768
Безперервна післядипломна медична освіта на місцевому рівні: результати впров...MCH-org-ua
Презентація на Національній підсумковій конференції за результатами впровадження україно-швейцарської Програми "Здоров’я матері та дитини" (Київ, 23 квітня 2015 р.)
http://motherandchild.org.ua/ukr/event/768
Внесок Програми у систему безперервної медичної освіти в УкраїніMCH-org-ua
Презентація на Національній підсумковій конференції за результатами впровадження україно-швейцарської Програми "Здоров’я матері та дитини" (Київ, 23 квітня 2015 р.)
http://motherandchild.org.ua/ukr/event/768
Швейцарсько-українська програма «Здоров'я матері та дитини»: Огляд історії пр...MCH-org-ua
Презентація Мартіна Рааба на Національній підсумковій конференції за результатами впровадження Програми (Київ, 23 квітня 2015 р.)
http://motherandchild.org.ua/ukr/event/768
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
CDSCO and Phamacovigilance {Regulatory body in India}
Anemia and Preemies: Contemporary Approach to Diagnostics, Preventive Measures, and Correction
1. Anemia and Preemies:
Contemporary Approach to
Diagnostics, Preventive Measures,
and Correction
Edward F. Bell
University of Iowa
edward-bell@uiowa.edu
Kyiv, 6 March 2013
2.
3. To Transfuse or Not To Transfuse?
At what hemoglobin level would you transfuse a
7-day-old 26-week preterm baby with birth
weight 800 grams?
1. Room air, no respiratory support?
2. Low FiO2 by nasal cannula or oxyhood?
3. Synchronized IMV via endotracheal tube, FiO2 0.50?
Or would you transfuse only if showing signs of
physiological compensation for anemia?
Or only if showing signs of compromise?
4. Outline of Presentation
Common causes of neonatal anemia
Strategies to reduce severity of anemia
Placental transfusion
Reduce phlebotomy blood loss
Support erythropoiesis
Transfusion guidelines
Any guidelines reduce transfusion frequency
What guidelines should we use?
What hemoglobin range is safest and most
beneficial?
5. Anemia in the Neonate
Physiological anemia
The hemoglobin declines in all newborn babies
Polycythemia is required by the fetus to assure
adequate tissue oxygen delivery in the presence of
physiologic hypoxemia in utero
Early clamping of the umbilical cord at birth limits
the initial blood volume
Red cells die faster than they are replaced by
erythropoiesis during the first months of life
6. Anemia in the Term or Preterm Baby
Inadequate placental transfusion
Fetal-maternal transfusion
Hemolytic disease of the newborn
Rh, ABO, or minor blood group isoimmunization
Hemoglobinopathy
RBC enzyme or membrane defect
Phlebotomy loss in NICU patient
7. Anemia in the Preterm Baby
Other factors, superimposed on physiological
anemia, result in “anemia of prematurity”
Early cord clamping even more likely in preterm
baby – urgency to start resuscitation
Phlebotomy losses (“hemorrhage into the
laboratory”)
Physiological anemia
+ early cord clamping
+ phlebotomy losses
= anemia of prematurity
10. Phlebotomy Blood Loss
in VLBW Babies
Cumulative phlebotomy losses typically reach
40 to 80 ml/kg and, in many babies, exceed
the baby’s blood volume
DIAGNOSTIC EXSANGUINATION
This is the single most important contributor
to anemia of the preterm, and it is the factor
that is most easily corrected
11. Phlebotomy Blood Loss
in VLBW Babies
How is this different in Ukraine compared to
U.S.?
Frequency of laboratory testing less
Volume of blood required for each test larger
Total phlebotomy loss may be similar (Is this
known?)
12. Transfusions for Preterm Babies
Very preterm babies are one of the most
heavily transfused patient groups
More than 90% of ELBW babies are
transfused, most multiple times
The mean number of transfusions per baby
ranges from 3 to 10 in published reports
Transfusion risks are very low in the U.S.,
but adverse effects occur nonetheless
13. Transfusion Risks
Transfusion reaction – minimized by proper
cross-matching
Infection
Hepatitis
HIV
Others, including unknown pathogens
Necrotizing enterocolitis?
Risks very low in U.S.; how high are they here?
14. Strategies for Avoiding Transfusion
Increase initial blood volume
Decrease blood loss
Support production of new RBCs
Use standardized transfusion
guidelines
19. Cord Clamping vs Milking
Delayed clamping of the umbilical cord has been shown
to have significant benefits for preterm infants.
However, delayed cord clamping has not gained wide
acceptance in obstetrical practice, in part because of the
preterm infant’s frequent need for resuscitation.
Many obstetricians and neonatologists are unwilling to
delay the resuscitation until the cord is clamped and cut
1 to 2 minutes after delivery.
Cord milking offers an alternative to delayed cord
clamping that may provide the same benefits without the
need to delay resuscitation.
20. Umbilical Cord Milking
Hosono S et al. Arch Dis Child Fetal Neonatal Ed.
2008; 93:F14
40 infants 24-28 weeks gestation
Randomized to early cord clamping or cord milking
Milking reduced need for transfusion
No need to delay resuscitation
No adverse effects
Rabe H et al. Obstet Gynecol.
2011; 117:205
58 infants <33 weeks
Milking vs delayed clamping
No difference
21. Cautions Regarding Delayed
Cord Clamping or Cord Milking
Impact on long-term neurodevelopmental
outcome unknown
Data are sparse for extremely preterm
babies, those who stand to gain the most
There may be groups of patients for whom
risks are greater, for example babies with
poor cardiac function – volume loading may
be harmful
22. Reducing Phlebotomy Blood Loss
Shown to be feasible – How?
Use methods and instruments that require
less blood
Avoid overdraw
“We wanted to be sure we had enough in case
we had to repeat the analysis. We didn’t want to
have to stick the baby again.”
Order only the laboratory studies that are
necessary; trainees tend to order too many
23. Supporting Erythropoiesis
Erythropoietin
Reduces need for transfusions but by only a
small amount (<1 transfusion per baby)
Most transfusions occur during the first week,
when erythropoietin is less effective
Cochrane review shows increased risk of severe
ROP with early erythropoietin
Not recommended for routine use
There may be a subgroup for whom benefit
outweighs risk, but this has not been defined
24. Supporting Erythropoiesis
Nutrition
Optimal erythropoiesis requires
adequate intakes of
Iron
Folate
Vitamin B12
Vitamin E
Protein
25. Limiting Donor Exposures
Transfusions cannot be avoided completely
Single donor transfusion programs can reduce
donor exposures to 1 or at most 2 donors for
anemic preterm babies
Modern storage media allow blood to be stored
for up to 42 days with acceptable quality; a unit
or part of a unit can be set aside to meet the
transfusion needs of a single preterm baby
26. Transfusion Guidelines
Introduction of standardized transfusion
guidelines has been shown in several studies
to reduce transfusions
But what should these guidelines be?
Can more restrictive guidelines (lower
hemoglobin thresholds) reduce transfusions?
If so, are there any harmful consequences of
restrictive guidelines?
27. Transfusion Guidelines
What do we know from existing clinical trials?
Two largest trials:
1. Iowa Trial
Bell EF et al. Pediatrics. 2005; 115:1685.
McCoy TE et al. Child Neuropsychol. 2011; 17:347.
Nopoulos P et al. Arch Pediatr Adolesc Med. 2011; 165:443.
2. PINT Trial
Kirpalani H et al. J Pediatr. 2006; 149:301.
Whyte RK et al. Pediatrics. 2009; 123:207.
28. Comparison of Iowa and PINT Trials
Experimental Design
Iowa Trial PINT Trial
Restrictive Liberal Restrictive Liberal
Participating 1 10
centers
No. of subjects 100 451
Treatment Randomized Randomized
allocation
Stratification Birth weight Birth weight, center
Mean BW (g) 954 958 771 769
Mean GA (wk) 28 28 26 26
29. Comparison of Iowa and PINT Trials
Transfusion Thresholds & Hemoglobin Separation
Iowa Trial PINT Trial
Restrictive Liberal Restrictive Liberal
Transfusion thresholds
(Hemoglobin, g/dl)
Highest 11.3 15.3 11.5 13.5
Lowest 7.3 10.0 7.5 8.5
Mean hemoglobin 8.3 11.0 10.1 11.2
Mean hemoglobin 2.7 1.1
difference
30. Transfusion Thresholds
Iowa Trial vs PINT Trial
60
Iowa Liberal
PINT Liberal
50
Hematocrit (%)
40 Iowa Liberal
Iowa Restrictive
30
PINT Liberal
PINT Restrictive
20
Restrictive
(both trials)
10
0
Intubated CPAP or Oxygen No Support
31. Comparison of Iowa and PINT Trials
Results
Iowa Trial PINT Trial
Restrictive Liberal Restrictive Liberal
No. of transfusions 3.3 5.2* 4.9 5.7
No. of donors 2.2 2.8 2.1 2.6*
Never transfused 10% 12% 11% 5%*
Apnea More frequent in 55% 60%
restrictive
Died 4% 2% 22% 18%
Brain injury (HUS) 12% 0%* 13% 16%
Death or brain injury 16% 2%* 31% 31%
* P < 0.05
32. Iowa Trial: Severe IVH and Cystic PVL
Liberal Restrictive P
Grade-4 IVH 0 4 0.054
Cystic PVL 0 4 0.115
Grade-4 IVH or cystic PVL 0 6 0.012
Caution: Composite outcome combining grade-4 IVH and
PVL was not planned; small numbers
33. PINTOS Outcomes: Odds Ratios
Restrictive vs Liberal
OR 95% CI p
1.50 0.94 , 2.21 0.09
1.18 0.72 , 1.93 0.52
1.32 0.53 , 3.27 0.55
1.74 0.98 , 3.11 0.06
2.16 0.19 , 24.1 0.53
1.45 0.32 , 6.58 0.63
Whyte et al. Pediatrics. 2009; 123:207-13
34. PINTOS Outcomes: Odds Ratios
Restrictive vs Liberal
OR 95% CI p
1.71 1.12, 2.61 0.01
1.18 0.72 , 1.93 0.52
1.32 0.53 , 3.27 0.55
1.81 1.12,2.93 0.02
2.16 0.19 , 24.1 0.53
1.45 0.32 , 6.58 0.63
Whyte and Kirpalani. Cochrane Database Syst Rev. 2011.
35. There are Possible Protective Effects of
Higher Hemoglobin Against Brain Injury,
but...
Iowa Trial
Composite analysis of grade-4 IVH or PVL was not
planned but was done post hoc
PINT Trial
Using preplanned Bayley II Mental Developmental Index
(MDI) threshold 70 (mean – 2 SD), there were
nonsignificant trends toward benefit with liberal
transfusion in cognitive outcome (MDI) and composite
outcome (death, cerebral palsy, MDI<70, blindness, or
deafness)
Using MDI threshold 85 (mean – 1 SD), these effects
were significant
36. Potential Mechanisms for
Neuroprotection by Higher Hemoglobin
Higher cerebral oxygen delivery
Higher arterial oxygen content
Higher blood volume after transfusion with
increased cerebral perfusion pressure
Less frequent apnea, eliminating
episodic hypoxia-ischemia and
subsequent reperfusion
37. The story continues...
School age assessment of Iowa Transfusion
Study subjects
54 children examined at school age (mean 12 y)
54% of original cohort (56% of survivors)
Evaluated with extensive neuropsychological
testing and brain MRI
38. School Age Assessment of Iowa
Transfusion Study Subjects
Children in the liberally transfused group, compared
to the restrictive group, performed more poorly on
measures of
Associative verbal fluency
Visual memory
Reading
And they had lower white matter volume by MRI
Girls were more affected than boys!
McCoy TE et al. Child Neuropsychol. 2011; 17:347.
Nopoulos P et al. Arch Pediatr Adolesc Med. 2011; 165:443.
.
39. Impact of Hematocrit on
Systemic Oxygen Transport
Oxygen
Flow content
Oxygen
transport
Anemic hypoxia Hyperviscosity
Hematocrit
40. Transfusion Thresholds
Iowa Trial vs PINT Trial
60
Iowa Liberal (HIGH)
PINT Liberal (INTERMEDIATE)
50
Hematocrit (%)
40 Iowa Liberal
Iowa Restrictive
30
PINT Liberal
PINT Restrictive
20
Restrictive (both trials)
(LOW)
10
0
Intubated CPAP or Oxygen No Support
41. Impact of Hematocrit on
Neurological Outcome
High Hematocrit Intermediate Low Hematocrit
Hematocrit
(Iowa Liberal) (Restrictive - both
(PINT Liberal) trials)
• Less apnea • More apnea
Iowa • Fewer US abnormalities • More US abnormalities
• Worse long-term outcomes • Better long-term outcomes
• Better 18-22 month • Worse 18-22 month
PINT outcomes outcomes
Are “intermediate” hematocrits (PINT liberal) the best?
42. Impact of Hematocrit on
Systemic Oxygen Transport
Oxygen
Flow content
Oxygen
transport
Intermediate
Anemic hypoxia Hematocrit Hyperviscosity
Hematocrit
43. Potential CNS Risks and Benefits of
High and Low Hematocrit
High Low
Anemic hypoxia and
Hyperviscosity lactic acidosis
Risks Iron excess (oxidation Increased cardiac work
and free radical injury)
More frequent apnea
Higher cerebral O2 Increased erythropoietin
delivery and perfusion production
pressure
Lower viscosity
Benefits
Less apnea (less
Avoid risk of iron excess
ischemia-reperfusion
injury) Less free radical injury
44. What Have We Learned from the
Iowa and PINT Trials?
Restrictive transfusion criteria can reduce
RBC transfusions, but only by a small amount
With a single-donor system, donor exposures
are not reduced
Higher transfusion thresholds may reduce
apnea frequency and severity
45. What Have We Learned from the
Iowa and PINT Trials?
Neurological implications are unclear
Higher transfusion thresholds may be
protective in the short term but harmful in the
long term
Or, it may be a matter of degree
High thresholds (Iowa liberal) may be harmful long
term
Intermediate thresholds (PINT liberal) may be
better
46. How Can We Solve This?
Evidence to date suggests that transfusion
threshold or hemoglobin level affects the
developing brain, but the evidence is not
strong enough to warrant treatment
recommendations
The most important outcome is survival
without neurodevelopmental impairment
The Iowa trial was underpowered to look at
neurodevelopmental outcomes, and the PINT
trial may have been, too
47. Conclusions
More research is needed
Until more is known, it would be unwise to
use lower transfusion thresholds than those
used in the low (restrictive) groups of the
Iowa and PINT trials, which were similar:
11.5 g/dl for young, sick babies
7.5 g/dl for older, stable babies
If you wish to go lower, show it is safe!
48. Comparison of Iowa and PINT Trials
Transfusion Thresholds and Hemoglobin Separation
Iowa Trial PINT Trial
Restrictive Liberal Restrictive Liberal
Transfusion thresholds
(Hemoglobin, g/dl)
Highest 11.3 15.3 11.5 13.5
Lowest 7.3 10.0 7.5 8.5
Mean hemoglobin 8.3 11.0 10.1 11.2
Mean hemoglobin 2.7 1.1
difference
49. To Transfuse or Not To
Transfuse?
At what hemoglobin level would you transfuse a
7-day-old 26-week preterm baby with birth
weight 800 grams?
1. Room air, no respiratory support: <7.5 g/dl
2. Low FiO2 by nasal cannula or head box: <9.5 g/dl
3. Synchronized IMV via endotracheal tube, FiO2 0.50:
<11.5 g/dl
Sooner if showing signs of physiological
compensation for anemia
Do not wait for signs of compromise